title: Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
abstract: The sodium glucose co-transporter 2 (SGLT2) inhibitor canagliflozin is a novel treatment option for adults with type 2 diabetes mellitus (T2DM). In patients with hyperglycemia, SGLT2 inhibition lowers plasma glucose levels by reducing the renal threshold for glucose (RTG ) and increasing urinary glucose excretion (UGE). Increased UGE is also associated with a mild osmotic diuresis and net caloric loss, which can lead to reductions in body weight and blood pressure (BP). After promising results from preclinical and phase I/II studies, the efficacy and safety of canagliflozin was evaluated in a comprehensive phase III development program in over 10,000 patients with T2DM on various background therapies. Canagliflozin improved glycemic control and provided reductions in body weight and BP versus placebo and active comparators in studies of up to 2 years' duration. Canagliflozin was generally well tolerated, with higher incidences of adverse events (AEs) related to the mechanism of action, including genital mycotic infections and AEs related to osmotic diuresis. Results from the preclinical and clinical studies led canagliflozin to be the first-in-class SGLT2 inhibitor approved in the United States, and support canagliflozin as a safe and effective therapeutic option across a broad range of patients with T2DM.
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Norm
authors: N
authors: Rosenthal
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Gary
authors: G
authors: Meininger
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Kirk
authors: K
authors: Ways
authors: Janssen Research & Development, LLC, San Diego, California.
authors: David
authors: D
authors: Polidori
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Mehul
authors: M
authors: Desai
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Rong
authors: R
authors: Qiu
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Maria
authors: M
authors: Alba
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Frank
authors: F
authors: Vercruysse
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Dainius
authors: D
authors: Balis
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Wayne
authors: W
authors: Shaw
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Robert
authors: R
authors: Edwards
authors: Janssen Research & Development, LLC, Fremont, California.
authors: Scott
authors: S
authors: Bull
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Nicholas
authors: N
authors: Di Prospero
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Sue
authors: S
authors: Sha
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Paul
authors: P
authors: Rothenberg
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: William
authors: W
authors: Canovatchel
authors: Janssen Research & Development, LLC, Raritan, New Jersey.
authors: Keith
authors: K
authors: Demarest
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D000068896:Canagliflozin / Q000494:pharmacology / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000077203:Sodium-Glucose Transporter 2 Inhibitors
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D000077203:Sodium-Glucose Transporter 2 Inhibitors; D000068896:Canagliflozin
keywords: SGLT2 inhibitor; antihyperglycemic agent; canagliflozin; type 2 diabetes